Emmaus Life Sciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.3M | $-3.3M | $-2.0M | $-2.1M | $-1.1M | $-2.3M | $-1.7M | $1.8M |
| Depreciation & Amortization | $14.0K | $15.0K | $15.0K | $15.0K | $4.0K | $5.0K | $5.0K | $5.0K |
| Depreciation | $14.0K | $15.0K | $15.0K | $15.0K | $4.0K | $5.0K | $5.0K | $5.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $0 | $1.0K | $7.0K | $9.0K | $-1.0K | $10.0K | $29.0K | $28.0K |
| Net Cash from Operating Activities | $1.7M | $-344.0K | $2.2M | $409.0K | $-2.9M | $279.0K | $343.0K | $148.0K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $6.0K | $-1.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $1.6M | $0 | $0 | $0 | $2.2M | $0 | $-2.0K | $1.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-1.5M | $-702.0K | $-362.0K | $-1.0M | $284.0K | $-345.0K | $-195.0K | $-438.0K |
| Net Change in Cash | $1.7M | $-1.1M | $1.8M | $-592.0K | $-448.0K | $-56.0K | $134.0K | $-270.0K |
| Free Cash Flow | — | — | — | — | — | — | $337.0K | $149.0K |